Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2

5(71.4%)

Phase 1

1(14.3%)

Phase 3

1(14.3%)

7Total

Phase 2(5)

Phase 1(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06993480Phase 2Active Not Recruiting

A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)

Role: lead

NCT07146100Recruiting

Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Injection

Role: lead

NCT07137910Phase 2Recruiting

A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)

Role: lead

NCT07246889Phase 3Active Not Recruiting

Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)

Role: lead

NCT06550128Phase 2Active Not Recruiting

Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB).

Role: lead

NCT07069569Phase 2Active Not Recruiting

A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs

Role: lead

NCT06115993Phase 1Active Not Recruiting

A Study to Evaluate the Safety and Efficacy of AHB-137 in Healthy Participants and HBeAg-negative Chronic Hepatitis B (CHB) Patients

Role: lead

NCT06829329Phase 2Active Not Recruiting

Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B (CHB)

Role: lead

All 8 trials loaded